These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 35994385)

  • 21. Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies.
    Chu WS; Ng J
    Front Immunol; 2021; 12():658038. PubMed ID: 33868303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adeno-Associated Virus (AAV) Vectors in the CNS.
    McCown TJ
    Curr Gene Ther; 2011 Jun; 11(3):181-8. PubMed ID: 21453285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.
    Rodríguez-Márquez E; Meumann N; Büning H
    Expert Opin Biol Ther; 2021 Jun; 21(6):749-766. PubMed ID: 33331201
    [No Abstract]   [Full Text] [Related]  

  • 24. Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes.
    Hamilton BA; Wright JF
    Front Immunol; 2021; 12():675897. PubMed ID: 34084173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evading the AAV Immune Response in Mucopolysaccharidoses.
    Piechnik M; Sawamoto K; Ohnishi H; Kawamoto N; Ago Y; Tomatsu S
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32414007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral immune responses to AAV gene therapy in the ocular compartment.
    Whitehead M; Osborne A; Yu-Wai-Man P; Martin K
    Biol Rev Camb Philos Soc; 2021 Aug; 96(4):1616-1644. PubMed ID: 33837614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adeno-associated virus (AAV) vectors in the CNS.
    McCown TJ
    Curr Gene Ther; 2005 Jun; 5(3):333-8. PubMed ID: 15975010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy of adeno-associated virus (AAV) vectors in preclinical models of ischemic stroke.
    Wang J; Zhu M; Sun J; Feng L; Yang M; Sun B; Mao L
    CNS Neurosci Ther; 2023 Dec; 29(12):3725-3740. PubMed ID: 37551863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors.
    Manning WC; Zhou S; Bland MP; Escobedo JA; Dwarki V
    Hum Gene Ther; 1998 Mar; 9(4):477-85. PubMed ID: 9525309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CpG-depleted adeno-associated virus vectors evade immune detection.
    Faust SM; Bell P; Cutler BJ; Ashley SN; Zhu Y; Rabinowitz JE; Wilson JM
    J Clin Invest; 2013 Jul; 123(7):2994-3001. PubMed ID: 23778142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical applications involving CNS gene transfer.
    Kantor B; McCown T; Leone P; Gray SJ
    Adv Genet; 2014; 87():71-124. PubMed ID: 25311921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety.
    Bucher K; Rodríguez-Bocanegra E; Dauletbekov D; Fischer MD
    Prog Retin Eye Res; 2021 Jul; 83():100915. PubMed ID: 33069860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineering adeno-associated virus vectors for gene therapy.
    Li C; Samulski RJ
    Nat Rev Genet; 2020 Apr; 21(4):255-272. PubMed ID: 32042148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical models to assess the immunogenicity of AAV vectors.
    Ertl HCJ
    Cell Immunol; 2019 Aug; 342():103722. PubMed ID: 29195742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy.
    Jayandharan GR; Aslanidi G; Martino AT; Jahn SC; Perrin GQ; Herzog RW; Srivastava A
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3743-8. PubMed ID: 21321191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune responses to AAV vectors: overcoming barriers to successful gene therapy.
    Mingozzi F; High KA
    Blood; 2013 Jul; 122(1):23-36. PubMed ID: 23596044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.
    Rapti K; Grimm D
    Front Immunol; 2021; 12():753467. PubMed ID: 34777364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
    Zaiss AK; Muruve DA
    Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery.
    Nidetz NF; McGee MC; Tse LV; Li C; Cong L; Li Y; Huang W
    Pharmacol Ther; 2020 Mar; 207():107453. PubMed ID: 31836454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Directed evolution of adeno-associated virus for efficient gene delivery to microglia.
    Lin R; Zhou Y; Yan T; Wang R; Li H; Wu Z; Zhang X; Zhou X; Zhao F; Zhang L; Li Y; Luo M
    Nat Methods; 2022 Aug; 19(8):976-985. PubMed ID: 35879607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.